Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study examined the FDA Adverse Events Reporting System and found new dermatologic adverse events associated with EGFR-TKIs in non-small cell lung cancer patients, such as specific skin, nail, and hair issues, that aren't currently listed on drug labels.

This review details the skin and hematological toxicities of tyrosine kinase inhibitors like erlotinib, gefitinib, and imatinib, and highlights ongoing concerns about cardiac toxicity, reporting no new clinical findings.

This review discusses various therapeutic strategies targeting platelet-derived growth factor signaling in diseases like cancer and atherosclerosis, and evaluates existing treatments without presenting new clinical data.

This study describes a newly recognized skin reaction associated with dasatinib, nilotinib, and ponatinib, marked by a lichenoid exanthem with severe pruritus that may necessitate discontinuation of therapy.

This review outlines dermatological toxicities associated with targeted cancer therapies and immunotherapies, emphasizing the need for collaborative management by oncologists and dermatologists but reports no new clinical findings.

This study observed that 71% of chronic myeloid leukemia patients treated with second-generation tyrosine kinase inhibitors experienced adverse cutaneous reactions, which were generally less severe than those caused by imatinib.

This report details a case of extensive leukotrichia induced by dasatinib in a patient with refractory chronic myelogenous leukemia.

Erlotinib can cause significant but temporary hair loss in lung cancer patients.

This case study reports generalized keratosis pilaris as a rare cutaneous side effect of nilotinib in a 40-year-old woman with chronic myeloid leukemia, highlighting the need for awareness among physicians.

This review explores the promising but varied effectiveness of tyrosine kinase inhibitors for treating different skin diseases, indicating their potential in dermatology while acknowledging the need for more evidence.

This study highlights the significant impact of cutaneous side effects associated with anticancer therapies, emphasizing the need for proactive management to improve patient quality of life and treatment adherence.

This study reports the case of an elderly patient with a keratosis pilaris-like skin eruption after beginning treatment with imatinib for chronic myeloid leukemia, discussing similar skin reactions to BCR-ABL inhibitors and exploring potential mechanisms behind these adverse cutaneous reactions.

This study described the safety profile of tyrosine kinase inhibitors in treating various solid tumors, finding that the observed toxicities were consistent with existing literature.

This study mapped the safety profile of EGFR-TKIs by analyzing FDA adverse event reports, highlighting unexpected reactions like intestinal obstruction and hypokalaemia with gefitinib and erlotinib.

This case report documents a 61-year-old woman treated with erlotinib who experienced the rare side effect of cicatricial alopecia.

This report presents the Taiwanese Dermatological Association's 2016 consensus on defining and managing skin toxicities from EGFR-TKI treatments, providing comprehensive guidelines for clinicians in Taiwan.

In this study, researchers found that applying topical aprepitant, which blocks substance P receptors, significantly reduced facial dermatitis and hair loss in rats experiencing erlotinib-induced skin side effects, highlighting the neurogenic inflammation's role and the protective effect of ROS inhibition.

No results are provided in this article as it lacks an available abstract, making it unclear what effects apremilast and tofacitinib have in a humanized mouse model of alopecia areata.

This study introduces ficlatuzumab, an anti-HGF monoclonal antibody, in combination with gefitinib in a phase 2 trial to address EGFR TKI resistance in Asian NSCLC patients.

This study found that, among patients with NSCLC after EGFR-TKI failure, pemetrexed is as effective as docetaxel but has fewer side effects, suggesting it may be a suitable salvage chemotherapy option.

In this report, two cases of non-small cell lung cancer treated with gefitinib showed unexpected hair growth, suggesting a potential new application of EGFR-TKIs for alopecia.

This study found that non-small-cell lung cancer patients experienced less adverse events with third-generation EGFR-TKIs compared to first and second generations, although fear of cancer progression, anxiety, and depression were still prevalent.

This source reviews the common skin-related side effects of tyrosine kinase inhibitors in treating endocrine cancers and emphasizes that proactive, multidisciplinary management can effectively control these adverse events without compromising cancer treatment efficacy.

This study reported a rare case of pityriasis rubra pilaris-like skin reaction in an 18-year-old woman after starting ponatinib treatment for relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia, which resolved after treatment adjustment and did not recur over 15 months.

Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.

This case report describes a patient who experienced rapid hair depigmentation after starting pazopanib for metastatic renal cell carcinoma, which may suggest therapy success despite being distressing.

The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.

This study developed a DPC cell line by introducing mutant CDK4, Cyclin D1, and TERT, making it a promising tool to study downstream signaling pathways activated by testosterone in androgenetic alopecia.

Using a combination of specific cell cycle regulators is better for safely keeping hair root cells alive indefinitely compared to cancer-related methods.

This article discusses the role and potential of plant stem cell extracts in cosmetics for their antioxidant and protective effects on skin cells, reporting no new clinical results; the authors highlight ecological and sustainable production methods.